Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule
Drug Enforcement Administration (DEA),
Department of Justice.
Fed Regist. 2004 Mar 18;69(53):12794-7.

ABSTRACT

This final rulemaking is issued by the Acting Deputy Administrator of the Drug Enforcement Administration (DEA) to place 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) and N-benzylpiperazine (BZP) into Schedule I of the Controlled Substances Act (CSA). This action by the DEA Acting Deputy Administrator is based on a scheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that 2C-T-7 and BZP meet the criteria for placement in Schedule I of the CSA. This final rule will continue to impose the regulatory controls and criminal sanctions of Schedule I substances on the manufacture, distribution, and possession of 2C-T-7 and BZP.

BZP
UK Alarm
Antidepressant
MDMA vs BZP and TFMPP
BZP versus TFMPP: how rewarding?
Antidepressant properties of BZP (Trelibet)
Piperazine-like compounds/designer drugs
Is BZP neuroprotective against MDMA/Ecstasy-induced neurotoxicity?
Chronic BZP exposure produces behavioural sensitization to methamphetamine

HOME
HedWeb
BLTC Research
The Good Drug Guide
Paradise-Engineering
The Hedonistic Imperative
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World